Download PDF
Thromb Haemost 1995; 74(01): 045-051
DOI: 10.1055/s-0038-1642651
Colloquium
The Haemophilias-An Update
Schattauer GmbH Stuttgart

Progress Towards Gene Therapy for the Hemophilias

Arthur R Thompson
University of Washington and the Puget Sound Blood Center, Seattle, WA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Thompson AR. Status of gene transfer for hemophilia A and B. Thromb Haemosta 1991; 66: 119-122
    PubMedGoogle Scholar
  • 2 urachi K, Yao S-N. Gene therapy of hemophilia B. Thromb Haemostas 1993; 70: 193-197
    PubMedGoogle Scholar
  • 3 Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460
    CrossrefPubMedGoogle Scholar
  • 4 Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932
    CrossrefPubMedGoogle Scholar
  • 5 Lozier JN, Brinkhous KM. Gene therapy and the hemophilias. JAMA 1994; 271: 47-51
    CrossrefPubMedGoogle Scholar
  • 6 Brownlee GG. Prospects for gene therapy of haemophilia A and B. Brit Med Bull 1995; 51: 91-105
    CrossrefPubMedGoogle Scholar
  • 7 Ah M, Lemoine NR, Ring CJA. The use of DNA viruses as vectors for gene therapy. Gene Therapy 1994; 1: 367-384
    PubMedGoogle Scholar
  • 8 Kotin RM. Prospect for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 5: 793-801
    CrossrefPubMedGoogle Scholar
  • 9 Michael SI, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther 1994; 1: 223-232
    PubMedGoogle Scholar
  • 10 Louis DSt, Verma IM. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci USA 1988; 85: 3150-3154
    CrossrefPubMedGoogle Scholar
  • 11 Palmer TD, Thompson AR, Miller AD. Production of human factor IX in animals by genetically modified skin fibroblasts: Potential therapy for hemophilia B. Blood 1989; 73: 438-445
    PubMedGoogle Scholar
  • 12 Matsushita T, Emi N, Takahashi I, Takamatsu J, Saito H. Construction and its expression of anew retroviral vector containing a human blood coagulation factor DC cDNA. Thrombos Res 1993; 69: 387-393
    CrossrefPubMedGoogle Scholar
  • 13 Axelrod JH, Read MS, Brinkhous KM, Verma IM. Phenotypic correction of factor DC deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci USA 1990; 87: 5173-5177
    CrossrefPubMedGoogle Scholar
  • 14 Lozier JN, Thompson AR, Hu P-C, Read M, Brinkhous KM, High KA, Curiel DT. Efficient transfection of primary cells in a caninehemophilia B model using adenoviras-polylysine-DNA complexes. Hum Gene Ther 1994; 5: 313-322
    CrossrefPubMedGoogle Scholar
  • 15 Gerrard AJ, Hudson DL, Brownlee GG, Watt FM. Towards gene therapy for haemophilia B using primary human keratinocytes. Nature Genetics 1993; 3: 180-183
    CrossrefPubMedGoogle Scholar
  • 16 Arnientano D, Thompson AR, Darlington G, Woo SLC. Expression of human factor DC in rabbit hepatocytes by retrovirus -mediated gene transfer: Potential for gene therapy of hemophilia. B. Proc Natl Acad Sci USA 1990; 87: 6141-6145
    PubMedGoogle Scholar
  • 17 Yao S-N, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K. Expression of human factor DC in rat capillary endothelial cells: toward somatic gene therapy for hemophilia. B. Proc Natl Acad Sci USA 1991; 88: 8101-8105
    PubMedGoogle Scholar
  • 18 Yao S-N, Kurachi K. Implanted myoblasts not only fuse with myofibers but also survive as muscle precursor cells. J Cell Science 1993; 105: 957-963
    PubMedGoogle Scholar
  • 19 Dai Y, Roman M, Naviaux R, Veima IM. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992; 89: 10892-10895
    CrossrefPubMedGoogle Scholar
  • 20 Palmer TD, Kreiter M, Thompson AR, Miller AD, Tapscott SJ. Myoblast- mediated gene therapy for factor DC deficiency. Thromb Haemost 1993; 69: 973 abstract
    PubMedGoogle Scholar
  • 21 Brazolot Millan CL, Hawley RG, Carter RF. Expression of canine factor DC by transduced long-term culture adherent cells, and their engraftment in the canine bone marrow compartment following autologous transplantation. Blood 1994; 84: 100a
    PubMedGoogle Scholar
  • 22 Israel DI, Kaufman RJ. Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 1990; 75: 1074-1080
    PubMedGoogle Scholar
  • 23 Hoeben RC, van derJagt RCM, Schoute F, van Tilburg NH, Verbeet MPh, Briet m, van Oimondt H, van der Eb AJ. Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 1990; 265: 7318-7323
    PubMedGoogle Scholar
  • 24 Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Therapy 1993; 4: 259-272
    CrossrefPubMedGoogle Scholar
  • 25 Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Bimstiel ML. In vivo production ofhuman factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus- agumented gene delivery. Proc Natl Acad Sci USA 1994; 91: 5148-5152
    CrossrefPubMedGoogle Scholar
  • 26 Dwariki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, Clift S, Bems A, Cohen LK. Gene therapy for hemophilia A: Production of therapeutic levels ofhuman factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023-1027
    CrossrefPubMedGoogle Scholar
  • 27 Lynch CM, Israel DI, Miller AD. Towards somatic cell gene therapy using endothelial cells. J Cell Biochem 1990; 14 E 222 abstract
    PubMedGoogle Scholar
  • 28 Smith KJ, Thompson AR. Labeled factor DC kinetics in patients with hemophilia. B. Blood 1981; 58: 625-629
    PubMedGoogle Scholar
  • 29 Gerrard AJ, Austen DEG, Brownlee GG. Subcutaneous injection of factor DC for the treatment of haemophilia. B. Brit J Haem 1992; 81: 610-613
    PubMedGoogle Scholar
  • 30 Lu D-R, Zhou J-M, Zheng B, Qui XF, Xue JL, Wang JM, Meng PL, Han FL, Ming BH, Wang XP. et al. Stage I clinical trial of gene therapy for hemophilia. B. Sci China [B series] 1993; 36: 1342-1351
    PubMedGoogle Scholar
  • 31 Miyanohara A, Johnson PA, Elam RL, Dai Y, Witztum JL, Vernia IM, Friedmann T. Direct gene transfer to the liver with herpes simplex virus type 1 vectors: Transient production of physiologically relevant levels of circulating factor DC. New Biologist 1992; 4: 238-246
    PubMedGoogle Scholar
  • 32 Smith GAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M. Adenovirus mediated expression of therapeutic plasma levels ofhuman factor DC in mice. Nature Genetics 1993; 5: 397-402
    CrossrefPubMedGoogle Scholar
  • 33 Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SLC. In vivo hepatic gene therapy: Complete albeit transient correction of factor DC deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357
    CrossrefPubMedGoogle Scholar
  • 34 Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson Am, Read MS, Brinkhous KM, Woo SL C. In Vivo Gene Therapy for Hemophilia B: Sustained Partial Correction in Factor DC Deficient Dogs. Science 1993; 262: 117-119
    CrossrefPubMedGoogle Scholar
  • 35 Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 91: 4086-4090
    CrossrefPubMedGoogle Scholar
  • 36 Schulman S. Intraperitoneal administration of factor VIE. Presented at the World Federation of Hemophilia XXth Congress, Athens, October, 1992 . abstract
    PubMedGoogle Scholar
  • 37 Hoeben RC, Fallaux FJ, van Tilburg NH, Cramer SJ, van Oimondt H, Brie E, van der Eb AJ. Toward gene therapy for hemophilia A: Long-term persistence of factor VIII secreting fibroblasts after transplantaiton into immunodeficient mice. Hum Gene Therapy 1993; 4: 179-186
    CrossrefPubMedGoogle Scholar
  • 38 Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-193
    CrossrefPubMedGoogle Scholar
  • 39 Yao S-N, Smith KJ, Kurachi K. Primary myoblast-mediated gene transfer: Persistent expression of human factor DC in mice. Gene Ther 1994; 1: 99-107
    PubMedGoogle Scholar
  • 40 Jallat S, Perraud F, Dalemans W, Balland A, Dietrle A, Faure T, Meuiien P, Pavirani A. Characterization of recombinant human factor IX expressed in transgenic mice and in derived trans-imortalized hepatic cell lines. EMBO J 1990; 9: 3295-3301
    PubMedGoogle Scholar
  • 41 Wang J, Yao SN, Sugahara Y, Tan J, Kurachi K. Optimization of myoblast- mediated gene transfer for hemophilia B gene therapy. Blood 1994; 84: 743a
    PubMedGoogle Scholar
  • 42 Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg DJM, van Oimondt H, Briet E, van der Eb AJ. Expression of the blood clotting factor VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85 in press
    PubMedGoogle Scholar
  • 43 Koeberl DD, Halbert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995; 6: 471-481
    PubMedGoogle Scholar
  • 44 Lubin IM, Healey JF, ScandeUa D, Runge MS, Lollar P. Elimination of a major inhibitor epitope in factor VIII. J Biol Chem 1994; 269: 8639-8641
    PubMedGoogle Scholar
  • 45 Kavanaugh MP, Miller DG, Zhang W, Law W, Kozak SL, Rabat D, Miller AD. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 1994; 91: 7071-7075
    CrossrefPubMedGoogle Scholar
  • 46 Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WRA, Clowes AW. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994; 93: 644-651
    CrossrefPubMedGoogle Scholar
  • 47 Salmons B, Gunzburg WH. Targeting of retroviral vectors forgene therapy. Hum Gene Ther 1993; 4: 129-141
    CrossrefPubMedGoogle Scholar
  • 48 Yee JK, Miyanohara A, LaPorte P, Bouic K, Bums JC, Friedmann T. A general method forthe generation ofhigh-titer, pantropic retroviral vectors: Highly efficient infection of primaiy hepatocytes. Proc Natl Acad Sci USA 1994; 91: 9564-9568
    CrossrefPubMedGoogle Scholar
  • 49 Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 363: 666-669
    PubMedGoogle Scholar
  • 50 Eisensmith RC, Fang B, Kay MA, Landen CN, Cross RE, Bellinger DA, Read MS, Hu PC, Brinkhous KM, Woo SLC. Gene therapy for hemophilia B: Cyclosporin treatment increases the persistence of adenovirus-mediated factor in expression in hemophilia B dogs. Blood 1994; 84: 255a
    PubMedGoogle Scholar
  • 51 Walter J, You O, Mickanin C, Baldwin HS, High KA. In utero injection in mice of adenoviral vectors expressing human factor IX results in low level gene transfer and does not interfere with fetal developoment. Blood 1994; 84: 742a
    PubMedGoogle Scholar
  • 52 DAy Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnik N, Veima IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for longterm expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405
    CrossrefPubMedGoogle Scholar
  • 53 Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenovirus improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 1994; 7: 362-369
    CrossrefPubMedGoogle Scholar
  • 54 Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci USA 1994; 91: 7257-7261
    CrossrefPubMedGoogle Scholar
  • 55 Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994; 91: 8915-8919
    CrossrefPubMedGoogle Scholar
  • 56 Liu HW, Ofosu FA, Chang PL. Expression of human factor IX by microencapsulated recombinant fibroblasts. Hum Gene Ther 1993; 4: 291-301
    CrossrefPubMedGoogle Scholar
  • 57 Lehmann-Bruinsma K, Johnson R, Akita G, Powell JS. Gene augmentation therapy increases hematocrit after expression of erythropoietin from allotypic cells in implanted immunoisolation chambers. Blood 1994; 84: 742a
    PubMedGoogle Scholar
  • 58 Kingdon HS, Brauker JH, Johnson RC, Carr-Brendel VE, Lozier JN, High KA. An immunoisolation device which facilitates cell-based prophylactic therapy for hemophilia. Blood 1993; 82: 446a
    PubMedGoogle Scholar